SKC is a strategic consultancy focused on the increasingly challenging market access environment of innovative drug products. We support the successful market access both on a strategic and an operational level. For nearly 20 years, our highly experienced team has been supporting our clients in solving their strategically complex questions.

The specific backgrounds of our colleagues in the field of Health Economics, Social Sciences, Medicine or Pharmacy contribute to fulfilling this mission.

We are partners of internationally operating pharma-, biotech and medtech companies, as well as of investors, whom we support as sparring partners, or whom we operationally guide through the entire market access process. As we enjoy facing strategic challenges, we particularly manage projects for orphan drug products, for ATMPs and for products which set new therapy standards.

Our systemic approach and our extensive network with clinical medicine and science allow us to place the patient in the center. We always start of by answering the question: what does the clinical reality look like? Our clients value or hands-on mindset and our custom-made project approach. We are strategic sparring partner and focused, agile implementer – depending on our individual client’s need. All our projects have one thing in common though. We always think from the end and anticipate all the challenges at the beginning.

We are enthusiastically committed to solving demanding situations. We are the Market Access Special Forces.

adthera is a contract development and manufacturing business focussed exclusively on cell and gene therapy “ATMP” Advanced Therapy Medicinal Products.  Taking cell therapy ideas and making them into workable medical interventions for patients, in a regulatory compliant and quality managed system, right first time.  A hugely experienced team of academic, industry and technology professionals whose purpose is to disrupt this nascent scientific area and bring medicines to patients at the optimal quality, as fast as possible, and more efficiently than before.  adthera is at the cutting edge of how this is being done (techniques, regulation, quality, digitisation, process engineering) and a “high tech” business, driven very strongly by their digital/data integration layer.  

adthera’s sentinel process and analytical site and headquarter is in Birmingham, UK where manufacturing is validated before transferring and scaling into their distributed GMP network that will expand into multiple sites in multiple countries.

Aglaris is a technology developer and provider that focuses on novel technologies for cell therapy manufacturing. Aglaris’ proprietary and transformative technology addresses critical weaknesses in the process development and manufacturing of T cell and other cell-based therapeutics. On top of its high-performance cell culture geometry, Aglaris is delivering CMC / PAT / Real-time Monitoring & Management to cell manufacturing. Both things together define a new generation of autonomous cell manufacturing equipment.

The company is led by industry experts, Mr. Steve Docksey, Dr David Horna and Dr Miquel Costa, who manage a growing international team with top engineers and scientists. Aglaris is located in state-of-the-art facilities and equipment at two technology parks: Stevenage Bioscience Catalyst in Stevenage, UK, and QUBE Technology Park in Madrid, Spain.